Ki67 Assessment by qRT-PCR in OncotypeDx® Breast Recurrent Score®: Low Correlation With IHC Assessment of ki67 and Prognostic Impact of ki67 RNA Level of Expression.

Zohair Selmani (zselmani@chu-besancon.fr)
Université de Besançon: Université de Franche-Comte

Chloé Molimard
Université de Franche-Comte Faculté de Sciences Médicales et Pharmaceutiques de Besançon: Université de Franche-Comte UFR Sciences médicales et pharmaceutiques

Alexis Overs
Université de Franche-Comte Faculté de Sciences Médicales et Pharmaceutiques de Besançon: Université de Franche-Comte UFR Sciences médicales et pharmaceutiques

Fernando Bazan
CHU Besançon Pôle cancérologie: Centre Hospitalier Universitaire de Besançon Pole cancerologie

Loïc Chaigneau
CHU Besançon Pôle cancérologie: Centre Hospitalier Universitaire de Besançon Pole cancerologie

Erion Dobi
Centre Hospitalier Universitaire de Besançon Pôle cancérologie: Centre Hospitalier Universitaire de Besancon Pole cancerologie

Nathalie Meneveau
CHU Besançon Pôle cancérologie: Centre Hospitalier Universitaire de Besançon Pole cancerologie

Laura Mansi
CHU Besançon Pôle cancérologie: Centre Hospitalier Universitaire de Besançon Pole cancerologie

Marie-Justine Paillard
CHU Besançon Pôle cancérologie: Centre Hospitalier Universitaire de Besançon Pole cancerologie

Guillaume Meynard
CHU Besançon Pôle cancérologie: Centre Hospitalier Universitaire de Besançon Pole cancerologie

Julien Viot
CHU Besançon Pôle cancérologie: Centre Hospitalier Universitaire de Besançon Pole cancerologie

Marie-Paule Algros
CHU Besancon: Centre Hospitalier Universitaire de Besançon

Christophe Borg
Université de Franche-Comte Faculté de Sciences Médicales et Pharmaceutiques de Besançon: Université de Franche-Comte UFR Sciences médicales et pharmaceutiques
Jean-Paul Feugeas
Université de Franche-Comte Faculté de Sciences Médicales et Pharmaceutiques de Besançon:
Universite de Franche-Comte UFR Sciences medicales et pharmaceutiques

Xavier Pivot
Universite de Strasbourg

Jean-Luc Prétet
Université de Franche-Comte Faculté de Sciences Médicales et Pharmaceutiques de Besançon:
Universite de Franche-Comte UFR Sciences medicales et pharmaceutiques

Elsa Curtit
Université de Franche-Comte Faculté de Sciences Médicales et Pharmaceutiques de Besançon:
Universite de Franche-Comte UFR Sciences medicales et pharmaceutiques

Research article

Keywords: Ki67, Breast cancer, Oncotype DX, prognostic impact, immunohistochemistry

DOI: https://doi.org/10.21203/rs.3.rs-525965/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Breast cancers expressing high levels of Ki67 are associated with poor outcomes. To provide individualized patient care, reliability of prognostic and predictive information deriving from Ki67 assessment is essential. Oncotype DX® test was designed for ER+/HER2- early-stage breast cancers to help adjuvant chemotherapy decision by providing a Recurrent Score® (RS®). RS® measures the expression of 21 specific genes from tumor tissue, including Ki67, and aim to predict the benefit of chemotherapy and the risk of distant recurrence.

The primary aim of this study was to assess the agreement between Ki67 RNA obtained with Oncotype DX® RS® and Ki67 IHC. Other objectives were to analyze the association between the event free survival (EFS) and the expression level of Ki67 RNA, and association between RS® and Ki67 RNA.

Methods: In a cohort of 98 patients with early ER+/HER2- breast cancers, we obtained: Recurrence score®, RNA level of Ki67 expression measured when assessing RS® and Ki67 tumor labelling by immunohistochemistry (Ki67 IHC). The Ki67 RNA was compared to the Ki67 IHC by Kappa Cohen test. With a mean follow-up of 57 months, the association between the event free survival (EFS) and Ki67 status was measured using R package survival.

Results: This population was essentially composed of no special type tumor (91%), N0 or Nmic (71%), grade 1 (62%), and tumor size pT1c (1-2 cm) (58%). The RS® values were <18 in 38% (n=37), 18-30 in 51% (n=50) and >30 in 11% (n=11) of the patients. A low agreement of 0.24 was found by Cohen's kappa test between Ki67 IHC and Ki67 RNA. Moreover, Ki67 RNA high tumors were significantly associated with the occurrence of events ($p=0.02$). On the other hand, we did not find any association between Ki67 IHC and EFS ($p=0.25$).

Conclusion: We observed of low agreement between expression level of Ki67 RNA and Ki67 protein labelling by IHC. Unlike Ki67 IHC and independently of the RS®, Ki67 RNA could have a prognostic value. It would be interesting to better assess the prognosis and predictive value of Ki67 RNA measured by qRT-PCR. The Ki67 RNA in medical routine could be a good support in countries where Oncotype DX® is not accessible.

Background

In terms of incidence, prevalence and mortality, breast cancer is in first place worldwide in women [1]. The vast majority of patients with breast cancer does not show detectable distant metastasis on diagnosis. Treatment of early breast cancer is based on surgical tumor resection with conditional lymph node dissection. Adjuvant systemic treatments including endocrine therapy (HT) and chemotherapy (CT) aim at the reduction of the distant recurrence rate and improvement of breast cancer specific survival. The decision of adjuvant therapeutic modalities is taken according to several prognostic and/or predictive
factors including patient age, tumor size, histological type and grade, lymph node involvement and expression on the tumor of hormone receptors for estrogen (ER) progesterone (PR), and the human epidermal growth factor receptor 2 (HER2) as well as the percentage of tumor cells expressing the nuclear proliferation marker Ki67 [2]. Genomic signatures were designed to give prognostic and predictive information to streamline adjuvant chemotherapy decision in ER-positive, HER2-negative breast cancer patients. Oncotype DX® Breast (ODX®) is the most widely used molecular signature in this setting and is included in treatment guidelines for estimating both the risk of distant recurrence and predicting adjuvant chemotherapy benefit. ODX® measures the RNA of 21 genes (16 cancer-associated genes and 5 housekeeping genes) and uses the expression pattern to calculate a recurrence score (RS®) that ranges between 0 and 100 [3]. The RS® result provides two types of information on tumor biology: (i) prognosis information: an estimate of the individual risk of distant cancer recurrence within 10 years, (ii) predictive information: an estimate of the likelihood of a benefit from chemotherapy [4–6].

Interestingly in breast cancer, Ki67 RNA (Ki67$_{RNA}$) is a parameter analyzed by several molecular signatures such as PAM50 and ODX [7]. Furthermore, Ki67 is an interesting biomarker in early breast cancer and breast cancers expressing high levels of Ki67 are associated with poor outcomes [8–10]. To provide individualized patient care in the concept of precision medicine, reliability of prognostic and predictive information deriving from Ki67 value is essential [11,12]. Some studies [13,14] indicate that lowering in Ki67 expression after neoadjuvant endocrine treatment may predict long-term outcome. Nevertheless, substantial variability in Ki67 staining of breast cancer tissue by immunohistochemistry (IHC) and interpretation was found between 30 routine pathology labs. Clinical use of Ki67 staining for therapeutic decisions should be considered with caution and only fully aware of lab-specific reference values [15]. Ki67 staining lacks scoring standardization; various studies have focused on assessment methodology standardization [16], interobserver reproducibility [17] and digital image analysis of Ki67 staining [18,19]. However, little is known about variability in IHC Ki67-labelling results between routine pathology labs [20,21] and its potential influence on interpretation of Ki67 levels in breast cancer. When using Ki67 assessment by IHC in order to consider an indication of adjuvant chemotherapy [22], clinicians should be aware of the low reproducibility of Ki67 scoring and its questionable analytical validity.

In the present study, we analyzed 98 patients tested by the Oncotype DX® Breast from June 2012 to April 2014. For this cohort, Ki67$_{RNA}$ level obtained in patients’ Oncotype DX® signatures were available. The primary aim of this study was to assess the agreement between Ki67$_{RNA}$ and Ki67 staining by IHC (Ki67$_{IHC}$). The other objectives were to analyze the association between the event free survival (EFS) and the expression level of Ki67$_{RNA}$ in ODX® signature; and association between RS® and Ki67$_{RNA}$.

**Methods**

2.1 Patients and tumors characteristics
Our study was an observational multicenter retrospective study collecting data on the real-life use of Oncotype DX Breast Recurrence Score® test by physicians in clinical practice settings in France. Patients eligibility criteria for this analysis correspond to the population for which the Oncotype DX® Breast Recurrence Score® test is validated, i.e. adult patients with a recent first diagnosis of a single early invasive breast tumor with ER+/HER2- status, plus available documentation of lymph node involvement as either N0 (node negative), Nmic (micrometastatic) or N1 (1-3 positive nodes). The following data were documented: patient age and sex, conventional clinical and pathological disease characteristics including histologic type, tumor size and grade, nodal status, receptor status including ER, PR, and HER2, and the Ki67 proliferation marker by IHC. Between 2012 and 2014, the RS® results were interpreted in three categories (low risk; intermediate risk; high risk with two cut-offs: 18 and 30). The event free survival (EFS) includes the local or metastatic relapse, other cancers and death with a mean follow-up of 57 months. Following the guidelines, the Oncotype DX® Breast Recurrence Score® test was realized after surgery and adjuvant treatments were adapted according to the RS®. The RS® values and the associated treatment (hormonal therapy plus/minus chemotherapy, or other modalities) were also collected.

2.2 Immunohistochemistry analyses.

The hormonal receptor status (ER and PR) was considered positive according to standardized European guidelines using a cut-off of $\geq 10\%$ stained tumor cell nuclei. The Ki67\textsubscript{IHC} evaluation was realized in 2 publics and 2 private pathological departments. In these structures, the Ki67\textsubscript{IHC} was assessed with monoclonal antibody MIB1 [16]. Based on recommendations established by St Gallen 2015, the Ki67\textsubscript{IHC}\textsuperscript{high} corresponding to Ki67 >20%, defined “high-risk” subpopulations of tumors [23].

2.3 Ki67\textsubscript{RNA} threshold determination and events statistical analyses

Descriptive statistics were used to summarize clinicopathological characteristics. Variables were described by the size and rate. After normalization, levels of Ki67\textsubscript{RNA} were distributed according to a Gaussian curve (Supplementary data 1). We have determined the optimal threshold using R package pROC version 1.16.1 [24]. The statistical comparison between IHC and ODX® was realized by Cohen’s kappa test.

Statistical analyzes were performed using R version 3.6.2 [25]. The survival follow-up was analyzed by the package survival version 3.1-8 [26].

Results

3.1. Characteristics of the patient population (Table 1)

Complete data sets from 98 breast cancer patients who underwent RS® testing were provided from 4 public treatment centers (public hospitals and university hospitals). The patients included were exclusively female and showed a wide age distribution (31 to 81 years) with a mean age of 57 years. The predominant tumor characteristics were no special type (NST) (91%), N0 or Nmic (71%), grade 1 (62%),
and tumor size pT1c (1-2 cm) (58%). All patients had ER positive/HER2 negative tumors. Table 1 shows the patient and disease characteristics of the full population. The RS® values were <18 in 38% (n=37), 18-30 in 51% (n=50) and >30 in 11% (n=11) of the patients. After surgery and collegial decision, all patients have received a treatment according the result of ODX® test (HT alone or CT-HT) in adjuvant situation. During the follow-up (57 months), we observed 19 events (19%): 3 local relapses, 10 metastatic relapses (bone, lung, liver and pancreas), 3 other cancers (contralateral breast, colorectal carcinoma and pancreatic carcinoma) and 3 deaths.

**Table 1.** Patient and disease characteristics in the population of ER positive/HER2 negative patients.

In this population, 98 women were included from June 2012 to April 2014. All patients were tested by Oncotype DX® Breast. The Nodal status was stratified in 3 groups: N0 (node negative), Nmic (micrometastatic) or N1 (1-3 positive nodes). The progesterone receptor status (PR) was considered positive according to standardized European guidelines using a cut-off of ≥10% stained tumor cell nuclei. All patients were ER positive and HER2 negative. The Ki67 IHC positivity was defined by the rate of >20% established by St Gallen 2015 recommendations. Almost, The Recurrence score results (RS®) are interpreted in three categories (low risk: RS® <18; intermediate risk: RS® = 18-30; high risk: RS® ≥31). The events include the local or metastatic relapse, other cancers and death.

*HT: Hormonal therapy, CT: Chemotherapy, NA: not analysed, NST: no special type.*
|                      | total (n=98) (%) |
|----------------------|------------------|
| **Age (years)**     |                  |
| < 50                 | 34               | 35% |
| ≥ 50                 | 64               | 65% |
| Mean                 | 57               |
| **Tumor size (mm)**  |                  |
| ≤10                  | 8                | 8%  |
| 10 - ≤20             | 57               | 58% |
| 20 - ≤50             | 32               | 33% |
| >50                  | 1                | 1%  |
| **Histological type**|                  |
| NST                  | 91               | 93% |
| Other                | 7                | 7%  |
| **Tumor grade**      |                  |
| Grade I              | 61               | 62% |
| Grade II             | 28               | 29% |
| Grade III            | 9                | 9%  |
| **PR status**        |                  |
| PR <10%              | 18               | 18% |
| PR ≥10%              | 80               | 82% |
| **Ki67 IHC (%)**     |                  |
| ≤20                  | 56               | 57% |
| >20                  | 39               | 40% |
| NA                   | 3                | 3%  |
| **Nodal status**     |                  |
| N0                   | 55               | 56% |
| Nmic                 | 15               | 15% |
| N1 (1-3 nodes)       | 28               | 29% |
| **Recurrence Score®**|                 |     |
3.2. Agreement between Ki67IHC and Ki67RNA
The Ki67IHC positivity rate of >20% [23] was used to define for the “high-risk” tumor group. We showed by ROC curve analysis an optimal threshold at 6.35 with a specificity of 48% and a sensitivity of 84%. With this cut off, the Ki67RNAnHigh were >6.35 and Ki67RNAnLow were <6.35 (Figure 1). A correlation between Ki67RNA expression and Ki67IHC score was found (R=0.36; p=3.10-4 IC 95% [0.2-0.5]) (Supplementary data 2). In the cohort, 29 tumors were Ki67nHigh and 29 were Ki67nLow by the two methods, which represent a match between the results in 58 patients (61%) (Table 2). Discordances were observed in 37 patients (39%): 10 samples were Ki67IHClow/Ki67RNAnHigh and 27 samples were Ki67IHChigh/Ki67RNAnLow. An agreement of 0.24 was found by Cohen’s kappa test.

Table 2. Agreement between Ki67RNA and Ki67IHC (n=95).

| Ki67RNA | Ki67IHC |
|---------|---------|
| High    | 29 (30.5%) |
| Low     | 10 (11%) |

Agreement of 0.24 by Cohen’s kappa test

3.3. Events-Free Survival among all patients according RS® groups and Ki67 status
A significant relationship was observed between EFS and the level of Ki67RNA expression (p=4.10-2) (Figure 2A) unlike Ki67IHC (p=0.25) (Figure 2B). However, we did not observe any significant difference on EFS according to the three RS® groups risk (p=0.4) (Figure 3). Using the age categories from the TAILORx study [27], the association between EFS and Ki67RNA status, was found only for women under 50 years (p=0.01) and not for women over 50 years (p=0.36) (Supplementary data 3). No association between Ki67IHC and EFS was observed (p>0.20).
3.4. Ki67RNA association with RS®
As expected, Ki67RNA levels were significantly associated with RS® (p=5.10-4) (Figure 4A). To a lesser extent, an association between ODX® test with Ki67IHC status has also been observed (p=0.013) (Figure 4B). Supplementary data 4 shows the distribution of Ki67IHC score and Ki67RNA level according to patient age, tumor grade and size, PR status, nodal status, Recurrence score, treatment and events.

Discussion

4.1. Study population
In this study, we focused on the Ki67RNA expression level of 98 patients. The majority of our data are consistent with the PONDx real life study [28] which found a female population over 50 (70%) with NST tumors (78%) ranging between 2-5 cm (89%), grade II (68%) and without lymph node involvement in 79% of cases. The PONDx cohort included more grade II than in our population (68% vs 29%) with a higher contingent of lobular carcinoma (13% vs 7%). In PONDx, RS® results by prognostic category used between 2012-2014 were: <18: 54%, 18-30: 36%; >30: 10%. Compared to this real-life study, the local cohort shows an inversion of the proportions between populations at low risk (38% vs 54%) and those at intermediate risk (51% vs 36%).
The few differences observed in the distribution of the risk groups established by the ODX® test can be explained by an over-representation of grade II tumors in the PONDx study. Our cohort is comparable to this largest population for most epidemiologic parameters.

4.2. Differences between Ki67RNA and Ki67IHC
Comparisons of Ki67 status showed a discrepancy between the two different types of evaluation. Indeed, half of Ki67RNAhigh (> 6.35) were found Ki67IHClow (Table 2). The observed correlation between the two techniques, is therefore weak even if significant (R=0.36, p=3.10-4; IC 95% [0.2-0.5]) (Supplementary data2). Technically, IHC shows greater variability [20,21] and is less reproducible than the quantification of mRNAs. Currently, there is no standardization for the interpretation of the Ki67 status by IHC [16]. As a consequence, it generates inter-site and inter-observer variability within the same site [17]. In contrast, the Oncotype test which is a molecular based and standardized test provides objective results that are independent of the observer.
Furthermore, the ODX test analyzes the level of Ki67 messenger RNAs in the tumor sample. This analysis therefore considers the transcripational status of the Ki67 gene level not only in tumor cells but also in associated cells such as lymphocytes, stromal or endothelial cells. Therefore, it is an overall estimate. By IHC, the protein expression is scored only on tumor cells. The two methods do not provide the same types of information on Ki67 status. These two types of evaluation of Ki67 are probably complementary because the Ki67IHC informs us about the tumor specific proliferation index and the Ki67RNA would reflect the proliferation of the tumor and its microenvironment. For all the reasons mentioned above, the association between RS® and Ki67IHC status is lower but remains significant (p=0.013).

4.3. Events free survival analyses
On the one hand in this study, adaptation of treatment based on RS® permit to obtain equivalent EFS in
populations with low and high risk of recurrence. We have modestly confirmed the efficiency of ODX® test. Indeed, the lack of association between RS® and EFS can be explained by the treatment (HT alone or CT-HT) performed according to the score. The clinical validity and utility of the RS® has been demonstrated prospectively across multiple studies in breast cancer patients worldwide including multiple validation studies as well as long-term prospective studies (TAILORx [27], WSG Plan B [29] and analyses from a prospective epidemiological database [30]). Based on level Ia evidence, the Oncotype DX test has been incorporated in leading internationally-accepted clinical guidelines on the treatment of early breast cancer (St. Gallen [31], ESMO [32], and ASCO [33]). This therapeutic adaptation will therefore smooth the differences between the categories of the ODX® test and at the same time demonstrates the value of the information provided by its score.

On the other hand, we were able to show that Ki67RNAhigh was significantly associated with the occurrence of events (p=0.02) but we did not find any association between Ki67IHC and EFS (p=0.25). Our data relate to a small population but leaves the possibility of a larger study in order to confirm these that Ki67RNA evaluation has a prognostic impact as RS®.

4.4. Correlation between Ki67RNA and RS®
As expected in our cohort, the RS® obtained is strongly associated with the Ki67RNA (p=5.10-4) which is one of the components of this test (Figure 4A). To optimize RS® interpretation, the TAILORx subgroup study shows a benefit of CT in women ≤50 years old with an RS® of 16 to 25 (p=0.004). CT could be avoided in women over 50 years old with a RS® <26, in women 50 years old or less with an RS® <16 [34]. Recently in San Antonio Breast cancer symposium, the results of RxPONDER study were presented [35]. And now, postmenopausal women with 1-3 positive nodes and RS® 0-25 can safely forego adjuvant CT without compromising invasive disease-free survival. The premenopausal women with positive nodes and RS 0-25 likely significantly benefit from chemotherapy [35].

Oncotype DX® Breast enables relevant net reductions in chemotherapy use, sparing patients from serious toxicities [7]. On this other side, its clinical impact and pharmacoeconomic benefit in routine care have been shown in 20 decision-impact studies [36–38]. However, in many places, the oncotype score remains inaccessible or not reimbursed [7,28,38]. This is why the evaluation of the level of Ki67RNA by a molecular biology techniques [39,40] could be a low-cost prognostic alternative in some countries. But this hypothesis will have to be validated during a prospective translational study.

Conclusions
We observed of low agreement between Ki67RNA tumor level measured by qRT-PCR and Ki67 protein labelling by IHC. Substantial variability in Ki67IHC of breast cancer tissue and interpretation have been shown and widely published. The clinical use of Ki67 labelling should be cautious and limited by the low reproducibility of Ki67 scoring and its questionable analytical validity.

Unlike Ki67IHC and independently of the RS®, Ki67RNA could have a prognostic value. The assessment of Ki67RNA by qRT-PCR on breast cancer tumor would be feasible and cost effective. It would be of great
clinical utility to better assess the prognosis and predictive value of Ki67\textsubscript{RNA}. Presentation of Ki67 status in Genomic Health report could also be helpful for therapeutic decisions on borderline situation.

**Declarations**

**Ethics approval and consent to participate**

All procedures performed in studies involving human participants were in accordance with the ethical standards of the national research committee and with the 1964 Helsinki Declaration and its later amendments. In France, this search is considered like a non-interventional study according to European legislation. All patients were individually informed that their data should be used to scientific research.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The datasets generated and analyzed during this study (birthdate, admission date, discharge date, date of death...), are available from the corresponding author on reasonable request.

**Competing interests**

ZS: Honoraria from Pfizer, Genomic Health

EC: Honoraria from Novartis, Pfizer, Daiichi, Genomic Health

FB: Honoraria from Roche, Novartis, Pfizer, Astra-Zeneca, Clovis, Daiichi.

CB: advisory board from Bayer, BMS, msd, servier and research grant from Roche

NM, JV, CM, AO, JLP, JPF, ED, LM, MPA, LC, MJP, GM, XP: have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Funding**

Not applicable.

**Authors’ contributions**

*Conception and design*: EC, ZS.

*Development of methodology*: ZS, EC.

*Acquisition of data*: EC, ZS, FB, ED, MN, NM, MJP, GM, JV, XP.
Analysis and interpretation of data: ZS, AO, CM, JLP, JPF.

Writing, review, and/or revision of the manuscript: ZS, CM, JLP, EC.

Administrative, technical, or material support: EC, ZS, JLP, MPA, JPF, CB.

Study supervision: EC, ZS.

Acknowledgements

We thank all patients who agreed to participate in this observational study. Their also thank Genomic Health, Inc. (now Exact sciences) and Mahi Y. for the Ki67RNA data. The authors are grateful to all participating physicians for their cooperation and for private and public anatomopathology departements (CH de Trevenans, Besancon Pathologie et le Dr Chargeboeuf M.) for their participation in IHC analyses.

References

1. Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;70:313–313.

2. Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28:1700–12.

3. Gluz O, Nitz U, Christgen M, Kates R, Clemens M, Kraemer S, et al. Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer. Eur J Cancer. 2016;S6–S6.

4. Curtit E, Mansi L, Maisonnette-Escot Y, Sautière J-L, Pivot X. Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX® Breast Recurrence Score Assay. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2017;43:921–30.

5. Pivot X, Mansi L, Chaigneau L, Montcuquet P, Thierry-Vuillemin A, Bazan F, et al. In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy? The Oncologist. 2015;20:344–50.

6. McVeigh TP, Hughes LM, Miller N, Sheehan M, Keane M, Sweeney KJ, et al. The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre. Eur J Cancer Oxf Engl 1990. 2014;50:2763–70.

7. Gligorov J, Pivot XB, Jacot W, Naman HL, Spaeth D, Misset J-L, et al. Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study. The Oncologist. 2015;20:873–9.
8. Domagala W, Markiewski M, Harezga B, Dukowicz A, Osborn M. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res. 1996;2:147–54.

9. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, et al. Ki-67 expression in breast carcinoma. Cancer. 2003;97:1321–31.

10. de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer. 2007;96:1504–13.

11. Hayes DF. Biomarker validation and testing. Mol Oncol. 2015;9:960–6.

12. Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;75:284–98.

13. Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F, et al. Letrozole Inhibits Tumor Proliferation More Effectively than Tamoxifen Independent of HER1/2 Expression Status. Cancer Res. 2003;63:6523–31.

14. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R, et al. Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast Cancer. JNCI J Natl Cancer Inst. 2007;99:167–70.

15. Focke CM, Bürger H, van Diest PJ, Finsterbusch K, Gläser D, Korschling E, et al. Interlaboratory variability of Ki67 staining in breast cancer. Eur J Cancer. 2017;84:219–27.

16. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. JNCI J Natl Cancer Inst. 2011;103:1656–64.

17. Polley M-YC, Leung SCY, Gao D, Mastropasqua MG, Zabaglo LA, Bartlett JMS, et al. An international study to increase concordance in Ki67 scoring. Mod Pathol. 2015;28:778–86.

18. Stålhammar G, Fuentes Martinez N, Lippert M, Tobin NP, Mølholm I, Kis L, et al. Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol. 2016;29:318–29.

19. Gudlaugsson E, Skaland I, Janssen EAM, Smaaland R, Shao Z, Malpica A, et al. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology. 2012;61:1134–44.

20. Mengel M, Wasielewski R von, Wiese B, Rüdiger T, Müller-Hermelink HK, Kreipe H. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol. 2002;198:292–9.

21. Ekholm M, Grabau D, Bendahl P-O, Bergh J, Elmberger G, Olsson H, et al. Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines – a Swedish survey with central re-assessment. Acta Oncol. 2015;54:1040–8.

22. Sonnenblick A, Francis PA, Azim HA, de Azambuja E, Nordenskjöld B, Gutiérrez J, et al. Final 10-year results of the Breast International Group 2–98 phase III trial and the role of Ki67 in predicting benefit
of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. Eur J Cancer. 2015;51:1481–9.

23. Focke CM, van Diest PJ, Decker T. St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods. Breast Cancer Res Treat. 2016;159:257–63.

24. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.

25. R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.

26. Therneau T. (2015). A Package for Survival Analysis in S_. version 2.38.

27. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015;373:2005–14.

28. Curtit E, Vannetzel J-M, Darmon J-C, Roche S, Bourgeois H, Dewas S, et al. Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: Real-life utilization and decision impact in French clinical practice. The Breast. 2019;44:39–45.

29. Gluz O, Nitz UA, Christgen M, Kates S, Shak S, Clemens M, et al. West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. J Clin Oncol. 2016;

30. Roberts MC, Miller DP, Shak S, Petkov VI. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database. Breast Cancer Res Treat. 2017;163:303–10.

31. Gnant M, Harbeck N, Thomssen C. St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. Breast Care. 2017;12:102–7.

32. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2015;26:v8–30.

33. Krop I, Ismaila N, Stearns V. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Focused Update Guideline Summary. J Oncol Pract. 2017;13:763–6.

34. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018;379:111–21.

35. Kalinsky K, Barlow WE, Meric-Bernstam F, Gralow JR, Albain KS, Hayes DF, et al. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy +/-chemotherapy in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative breast cancer with recurrence score of 25 or less: SWOG S1007. San Antonio; 2020.

36. Davidson JA, Cromwell I, Ellard SL, Lohrisch C, Gelmon KA, Shenkier T, et al. A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in
oestrogen receptor positive node negative breast cancer. Eur J Cancer. 2013;49:2469–75.

37. Holt S, Bertelli G, Humphreys I, Valentine W, Durrani S, Pudney D, et al. A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNlmi, ER-positive breast cancer in the UK. Br J Cancer. 2013;108:2250–8.

38. Nerich V, Curtit E, Bazan F, Montcuquet P, Villanueva C, Chaigneau L, et al. [Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region]. Bull Cancer (Paris). 2014;101:681–9.

39. Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, et al. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017;35:1061–9.

40. Issac MSM, Yousef E, Tahir MR, Gaboury LA. MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis. Neoplasia N Y N. 2019;21:1015–35.

Figures
Threshold determination, specicity and sensitivity of Ki67RNA. Threshold of Ki67RNA was determined using package pROC version 1.16.1 (pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics, 12, p.77. DOI: 10.1186/1471-2105-12-77). An optimal threshold of Ki67RNA at 6.35 units was found with a specificity of 48% and sensitivity of 84%.

Figure 1
Figure 2

Events-Free Survival according Ki67 status by ODX® test and by immunochemistry. The survival follow-up was analyzing by the package survival version 3.1-8 (26). The events include the local or metastatic relapse, other cancers occurrence and death with a mean follow-up of 57 months. (A) Ki67RNA were analyzed according to two groups using the 6.35 units’ threshold. (B) The Ki67IHC were analyzed according to two groups using the rate of >20%.
Figure 3

Events-Free Survival among all patients according RS® groups. The survival follow-up was analyzed by the package survival version 3.1-8 [26]. The events include the local or metastatic relapse, other cancers occurred and death with a mean follow-up of 57 months. The RS® are interpreted in three categories (low risk: RS® <18; intermediate risk: RS®= 18-30; high risk: RS® >30).
Figure 4

Association between RS® and Ki67 status. A. The association of RS® with Ki67RNA were analyzed according to the 6.35 units’ threshold. B. The association of RS® with Ki67IHC were analyzed using the rate of >20%.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- ADDITIONALFILES.docx